MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...
Building on more than two decades of research, a study by MIT neuroscientists at The Picower Institute for Learning and ...
According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...
To see if a treatment that targets NMDA receptors might be effective in fragile X, they tried an experimental drug called Glyx-13. This drug binds to the 2B subunit of NMDA receptors to augment ...
To see if a treatment that targets NMDA receptors might be effective in fragile X, they tried an experimental drug called Glyx-13. This drug binds to the 2B subunit of NMDA receptors to augment ...